Stay updated with breaking news from Alpine Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The "Global Musculoskeletal Partnering 2016-2023: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's...
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) saw a large increase in short interest in May. As of May 15th, there was short interest totalling 1,150,000 shares, an increase of 8.5% from the April 30th total of 1,060,000 shares. Based on an average daily volume of 107,200 shares, the short-interest ratio is presently 10.7 […]
The CTLA-4 inhibitors pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis. LAS
/PRNewswire/ -- DelveInsight's 'CTLA-4 Inhibitors Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and...
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) saw a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 1,150,000 shares, a growth of 8.5% from the April 30th total of 1,060,000 shares. Based on an average daily volume of 107,200 shares, the days-to-cover ratio […]